Walleye Capital
CBIO

Walleye Capital’s Crescent Biopharma CBIO Stock Holding History

Walleye Capital’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-388
Closed -$146K – 894
2020
Q2 		$146K Sell
388
-1,438
-79% -$407K 0.03% 473
2020
Q1 		$417K Buy
1,826
+1,698
+1,327% +$649K 0.09% 266
2019
Q4 		$67K Sell
128
-182
-59% -$98.5K ﹤0.01% 1454
2019
Q3 		$134K Buy
+310
New +$199K 0.01% 1342

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Walleye Capital's CBIO Position: Q3 2020 in Review

Walleye Capital sold out of Crescent Biopharma (CBIO) in Q3 2020, closing a stake of 388 shares — an estimated $146K sold.

Walleye Capital first reported a position in CBIO in Q3 2019 and held it in 4 quarters. The position peaked at $417K in Q1 2020. 80 funds tracked by Wall St. Rank hold CBIO as of Q3 2020.

  • Walleye Capital reported no remaining Crescent Biopharma position as of Q3 2020 after selling out during the quarter.
  • Walleye Capital sold 388 Crescent Biopharma shares in Q3 2020, an estimated $146K.
  • Walleye Capital first reported a position in Crescent Biopharma in Q3 2019 and held it in 4 quarters.
  • Walleye Capital's Crescent Biopharma position peaked at $417K in Q1 2020.
  • 80 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2020.

Based on Walleye Capital's 13F filing for Q3 2020, filed 16 Nov 2020.